GLP-1 vs. GLP-3 Peptide Therapy: Comparing Efficacy and Tolerability in Weight Loss Trials
Clinical Advisory Team · July 18, 2026 · ~1 min read
Two Peptide Classes, One Crowded Comparison
A research coordinator fielding intake calls at a metabolic health clinic hears the same question in a dozen different phrasings every week: which peptide actually works better, the GLP-1 or the newer "GLP-3" compound a patient read about in a forum post. The question sounds simple. The honest answer requires unpacking what each term refers to before any efficacy number means anything.
This matters because the phrase GLP-1 vs GLP-3 peptide therapy has become shorthand across research communities for a comparison that is, pharmacologically, between a single-receptor agonist and a multi-receptor agonist — not between two versions of the same hormone class. Getting that distinction wrong leads to apples-to-oranges reasoning about dosing, side effects, and trial data that does not hold up under scrutiny.
The analysis below works through the terminology, the receptor pharmacology, and the head-to-head trial data as it currently exists, drawing on published phase 2 and phase 3 results rather than marketing claims from any peptide supplier. Where trials differ in duration, dose, or population, that is flagged explicitly, because cross-trial comparison without those caveats is a common source of misleading percentage claims in this space.
Frequently asked questions
Is GLP-3 a real receptor like GLP-1?
No. GLP-1 receptor is a well-characterized class B GPCR with FDA-approved agonists. "GLP-3" is not a recognized endogenous receptor in peer-reviewed endocrinology literature; the term is used informally in research and supplier contexts to describe triple-hormone-receptor agonist peptides such as retatrutide, which acts on GIP, GLP-1, and glucagon receptors.
How does retatrutide compare to semaglutide for weight loss?
In retatrutide's phase 2 trial (NCT04881721), the 12 mg dose produced 24.2% mean weight loss at 48 weeks versus semaglutide 2.4 mg's 14.9% at 68 weeks in STEP 1 (NCT03548935). Trials differ in duration, dose, and population, so the comparison is indirect, not head-to-head.
Which has worse side effects, GLP-1 or triple-agonist peptides?
Both classes show gastrointestinal adverse events as the dominant tolerability issue, mainly nausea, diarrhea, and vomiting during dose escalation. Reported discontinuation rates for adverse events cluster between roughly 4% and 7% across semaglutide, tirzepatide, and retatrutide trials, without a clear tolerability advantage for either class based on current data.
Is there a head-to-head trial comparing GLP-1 and triple-agonist peptides directly?
As of mid-2026, no completed phase 3 head-to-head trial directly randomizes semaglutide against retatrutide in the same cohort. Comparisons rely on cross-trial data from STEP, SURMOUNT, and retatrutide's phase 2 program, which differ in duration, dosing, and baseline population characteristics.
Are triple-agonist peptides FDA approved?
No. As of this writing, retatrutide remains investigational and has not completed phase 3 trials or received FDA approval. Semaglutide (Wegovy) and tirzepatide (Zepbound) are FDA-approved for chronic weight management; any triple-agonist peptide obtained outside a clinical trial or prescription pathway falls outside approved, monitored use.